Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route.
The aim of the present study was to prepare and evaluate a rasagiline-loaded chitosan glutamate nanoparticles (RAS-CG-NPs) by ionic gelation of CG with tripolyphosphate anions (TPP). RAS-loaded CG-NPs were characterized for particle size, size distribution, encapsulation efficiency and in vitro drug release. The mean particles size, polydispersity index (PDI) and encapsulation efficiency was found to be 151.1 ± 10.31, 0.380 ± 0.01 and 96.43 ± 4.23, respectively. Biodistribution of RAS formulations in the brain and blood of mice following intranasal (i.n.) and intravenous (i.v.) administration was performed using HPLC analytical method. The drug concentrations in brain following the i.n. of CG-NPs were found to be significantly higher at all the time points compared to both drug (i.n.) and drug CG-NPs (i.v.). The Cmax (999.25 ng/ml) and AUC (2086.60 ng h/ml) of formulation CG-NPs (i.n) were found to be significantly higher than CG-NPs (i.v.) and RAS solution (i.n.). The direct transport percentage (DTP%) values of RAS-loaded CG-NPs (i.n.) as compared to drug solution (i.n.) increased from 66.27 ± 1.8 to 69.27 ± 2.1%. The results showed significant enhancement of bioavailability in brain, after administration of the RAS-loaded CG-NPs which could be a substantial achievement of direct nose to brain targeting in Parkinson's disease therapy.
a Department of Pharmaceutics and.
Deepti
D
Mittal
a Department of Pharmaceutics and.
Shadab
S
Md
b Department of Pharmacology , Faculty of Pharmacy , Jamia Hamdard , New Delhi , India.
Quamrul
Q
Hasan
a Department of Pharmaceutics and.
Mohammad
M
Fazil
a Department of Pharmaceutics and.
Asgar
A
Ali
a Department of Pharmaceutics and.
Sanjula
S
Baboota
a Department of Pharmaceutics and.
Javed
J
Ali
D000281:Administration, Intranasal; D000818:Animals; D001682:Biological Availability; D001921:Brain / Q000378:metabolism*; D002626:Chemistry, Pharmaceutical; D048271:Chitosan / Q000737:chemistry; D004339:Drug Compounding; D016503:Drug Delivery Systems; D006041:Goats; D007189:Indans / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D051379:Mice; D053758:Nanoparticles; D009297:Nasal Mucosa / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010300:Parkinson Disease / Q000188:drug therapy; D014018:Tissue Distribution
D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline; D048271:Chitosan
Bioavailability; Parkinson disease; brain disease; nanoparticles; rasagiline